Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9566637 | 0.94 | SMN1; SMN2 (0.45) | GAAABCB1LMNAMAPTATM | |
| SCHEMBL12871748 | 0.90 | GAA (0.43) | GAAABCB1LMNAMAPTATM | |
| SCHEMBL4580348 | 0.82 | ABCB1 (0.48) | GAAABCB1LMNAMEN1KMT2A | |
| SCHEMBL4579151 | 0.78 | MAPT (0.47) | GAALMNAMAPTMEN1KMT2A | |
| SCHEMBL30732620 | 0.78 | ABCB1 (0.46) | GAAABCB1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL30732527 | 0.77 | ABCB1 (0.54) | GAAABCB1MAPTKMT2AHTT | |
| SCHEMBL4615298 | 0.76 | ABCB1 (0.43) | GAAABCB1LMNAMAPTMEN1 | |
| SCHEMBL11224199 | 0.76 | GAA (0.42) | GAAABCB1LMNAMAPTMEN1 | |
| SCHEMBL6865356 | 0.74 | GAA (0.51) | GAALMNAMAPTATMMEN1 | |
| SCHEMBL12871755 | 0.74 | ATM (0.42) | GAALMNAMAPTATMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351389-B2 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 2008-04-01 | — | — | US | disclosed |
| US-7351389-B2 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 2008-04-01 | — | — | US | disclosed |
| US-20050090689-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 2005-04-28 | — | — | US | disclosed |
| US-6875864-B2 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 2005-04-05 | — | — | US | disclosed |
| US-20030171561-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO SUISSE SA (CH) | 2003-09-11 | — | — | US | disclosed |
| EP-0543482-B1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INT BV (NL) | 2002-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171561-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | ARGLU1, PRMT1, AADAC | GAA 4341/4885ABCB1 1927/4885LMNA 3524/4885 |
| US-20050090689-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | AADAC, ANXA3, AAAS | GAA 3645/4885ABCB1 1331/4885LMNA 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.